PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 01:40PM GMT
Release Date Price: €36.6 (+1.67%)
David Neil Lebowitz
Citigroup Inc., Research Division - Research Analyst

Good morning. I'd like to welcome you all once again to the Citi's 18th Annual Biopharma Conference, and we're pleased to have with us in this session, the team from PTC Therapeutics. I would recommend anyone to go to the Citi website to look at any disclosures. But with that, I guess it's been a pretty busy year from PTC from both the corporate and from a therapeutic perspective. So if you could start and dive in, talk about the history of PTC, what the overall mission of the company is? And what types of changes have occurred?

Matthew B. Klein
PTC Therapeutics, Inc. - CEO & Director

Sure. David, thank you. So Matt Klein, CEO of PTC. And as you said, it's been a very exciting year for us. PTC celebrated its 25th anniversary in 2023. We were founded in 1998 with the mission of using innovative science to develop transformative therapies for patients with high unmet medical need. We've succeeded in that mission, and we've built a global biopharmaceutical company that discovers,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot